These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
920 related articles for article (PubMed ID: 1716432)
41. Maintenance of immunologic self-tolerance by nonimmunogenic forms of antigen. Swanborg RH Clin Exp Immunol; 1976 Dec; 26(3):597-600. PubMed ID: 64328 [TBL] [Abstract][Full Text] [Related]
42. Induction of experimental allergic encephalomyelitis in suckling Lewis rats: role of age and type of sensitizing neuroantigen. Fujinami RS; Paterson PY J Immunol; 1977 Nov; 119(5):1634-8. PubMed ID: 72104 [No Abstract] [Full Text] [Related]
43. [Therapeutic effect of myelin basic protein and synthetic encephalitogenic peptide in guinea pigs with experimental allergic encephalomyelitis]. Belik IaV; Terletskaia IaT; Kozulina EP; Syrovatskaia LP; Gershkovich AA Vopr Med Khim; 1978; 24(3):372-7. PubMed ID: 78577 [TBL] [Abstract][Full Text] [Related]
44. Cell-mediated immunity to myelin basic protein in Lewis rats made unresponsive to experimental allergic encephalomyelitis. McGraw TP; Swanborg RH Eur J Immunol; 1978 Dec; 8(12):905-9. PubMed ID: 365547 [TBL] [Abstract][Full Text] [Related]
45. Protection against experimental allergic encephalomyelitis with peptides derived from myelin basic protein: presence of intact encephalitogenic site is essential. Driscoll BF; Kies MW; Alvord EC J Immunol; 1976 Jul; 117(1):110-4. PubMed ID: 58930 [TBL] [Abstract][Full Text] [Related]
46. Induction of antigen-specific tolerance for the treatment of ongoing, relapsing autoimmune encephalomyelitis: a comparison between oral and peripheral tolerance. Kennedy KJ; Smith WS; Miller SD; Karpus WJ J Immunol; 1997 Jul; 159(2):1036-44. PubMed ID: 9218627 [TBL] [Abstract][Full Text] [Related]
47. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. V. Hierarchy of suppression by myelin basic protein from different species. Miller A; Lider O; al-Sabbagh A; Weiner HL J Neuroimmunol; 1992 Aug; 39(3):243-50. PubMed ID: 1379607 [TBL] [Abstract][Full Text] [Related]
48. Immunologic activity of myelin basic protein in strain 2 and strain 13 guinea pigs. Kies MW; Driscoll BF; Lisak RP; Alvord EC J Immunol; 1975 Jul; 115(1):75-9. PubMed ID: 50359 [TBL] [Abstract][Full Text] [Related]
49. Neural antigens and induction of myelination inhibition factor. Seil FJ; Kies MW; Bacon M J Immunol; 1975 Feb; 114(2 Pt 1):630-4. PubMed ID: 47359 [TBL] [Abstract][Full Text] [Related]
50. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. VI. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization. Miller A; Zhang ZJ; Sobel RA; al-Sabbagh A; Weiner HL J Neuroimmunol; 1993 Jul; 46(1-2):73-82. PubMed ID: 7689596 [TBL] [Abstract][Full Text] [Related]
51. Induction and clinical scoring of chronic-relapsing experimental autoimmune encephalomyelitis. Beeton C; Garcia A; Chandy KG J Vis Exp; 2007; (5):224. PubMed ID: 18979022 [TBL] [Abstract][Full Text] [Related]
52. Studies on autoimmune encephalomyelitis in the guinea pig. II. An in vitro investigation on the nature, properties, and specificity of the serum-demyelinating factor. Lebar R; Boutry JM; Vincent C; Robineaux R; Voisin GA J Immunol; 1976 May; 116(5):1439-46. PubMed ID: 58035 [TBL] [Abstract][Full Text] [Related]
53. Treatment of autoimmune disease by oral tolerance to autoantigens. Whitacre CC; Gienapp IE; Meyer A; Cox KL; Javed N Clin Immunol Immunopathol; 1996 Sep; 80(3 Pt 2):S31-9. PubMed ID: 8811061 [TBL] [Abstract][Full Text] [Related]
54. Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis. Johns TG; Kerlero de Rosbo N; Menon KK; Abo S; Gonzales MF; Bernard CC J Immunol; 1995 May; 154(10):5536-41. PubMed ID: 7537310 [TBL] [Abstract][Full Text] [Related]
55. Effect of oral administration of pig spinal cord hydrolysate on clinical and histopathological symptoms of experimental allergic encephalomyelitis in rats. Kasarełło K; Gadamski R; Piotrowski P; Kurzepa K; Kwiatkowska-Patzer B; Lipkowski AW Folia Neuropathol; 2015; 53(2):128-38. PubMed ID: 26216115 [TBL] [Abstract][Full Text] [Related]
56. Role of ethanolamine phosphate in the hippocampus of rats with acute experimental autoimmune encephalomyelitis. Aguado-Llera D; Puebla-Jiménez L; Barrios V; Hernández-Pinto A; Arilla-Ferreiro E Neurochem Int; 2011 Jan; 58(1):22-34. PubMed ID: 20974204 [TBL] [Abstract][Full Text] [Related]
57. [Chronic relapsing experimental allergic encephalomyelitis in Lewis rats as a model of multiple sclerosis]. Zaprianova E; Deleva D; Bakalska M; Filchev N Morfologiia; 1997; 112(6):25-8. PubMed ID: 9606089 [TBL] [Abstract][Full Text] [Related]
58. Suppression of experimental allergic encephalomyelitis by alpha 2-macroglobulin. Hunter N; Weston KM; Bowern NA Immunology; 1991 May; 73(1):58-63. PubMed ID: 1710603 [TBL] [Abstract][Full Text] [Related]
59. Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW.1AV1 rats. Sakuma H; Kohyama K; Park IK; Miyakoshi A; Tanuma N; Matsumoto Y Brain; 2004 Oct; 127(Pt 10):2201-13. PubMed ID: 15282218 [TBL] [Abstract][Full Text] [Related]
60. Role of retinal pigment epithelium in the development of experimental autoimmune uveitis. Konda BR; Pararajasegaram G; Wu GS; Stanforth D; Rao NA Invest Ophthalmol Vis Sci; 1994 Jan; 35(1):40-7. PubMed ID: 8300362 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]